


This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (Previously presented) A compound of formula



wherein

R¹ represents an A-B-D group wherein

- (I) A denotes

- (a) a C₁₋₆-alkyl group substituted by a phenyl group, where the C₁₋₆-alkyl group may be substituted by one to twelve fluorine atoms and the phenyl ring may be substituted by the groups R¹⁰ to R¹⁴ and
 - i. R¹⁰ denotes
 - a. a fluorine, chlorine, bromine or iodine atom,
 - b. a C₁₋₄-alkyl, hydroxy, or C₁₋₄-alkyloxy group,
 - c. a nitro, amino, C₁₋₃-alkylamino, di-(C₁₋₃-alkyl)amino, cyano-C₁₋₃-alkylamino, [N-(cyano-C₁₋₃-alkyl)-N-C₁₋₃-alkyl-amino], C₁₋₃-alkyloxy-carbonyl-C₁₋₃-alkylamino, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-

- yl, piperazin-1-yl, 4-(C₁₋₃-alkyl)-piperazin-1-yl, C₁₋₃-alkyl-carbonylamino, arylcarbonylamino, aryl-C₁₋₃-alkyl-carbonylamino, C₁₋₃-alkyloxy-carbonylamino, aminocarbonylamino, C₁₋₃-alkyl-amino-carbonylamino, di-(C₁₋₃-alkyl)aminocarbonylamino, C₁₋₃-alkyl-sulphonylamino, bis-(C₁₋₃-alkylsulphonyl)-amino, aminosulphonylamino, C₁₋₃-alkylamino-sulphonylamino, di-(C₁₋₃-alkyl)amino-sulphonylamino, morpholin-4-yl-sulphonylamino, (C₁₋₃-alkylamino)thiocarbonylamino, (C₁₋₃-alkyloxy-carbonylamino)carbonylamino, arylsulphonylamino or aryl-C₁₋₃-alkyl-sulphonylamino group,
- d. an N-(C₁₋₃-alkyl)-C₁₋₃-alkyl-carbonylamino, N-(C₁₋₃-alkyl)-arylcarbonylamino, N-(C₁₋₃-alkyl)-aryl-C₁₋₃-alkyl-carbonylamino, N-(C₁₋₃-alkyl)-C₁₋₃-alkyloxy-carbonylamino, N-(aminocarbonyl)-C₁₋₃-alkylamino, N-(C₁₋₃-alkyl-aminocarbonyl)-C₁₋₃-alkylamino, N-[di-(C₁₋₃-alkyl)aminocarbonyl]-C₁₋₃-alkylamino, N-(C₁₋₃-alkyl)-C₁₋₃-alkyl-sulphonylamino, N-(C₁₋₃-alkyl)-arylsulphonylamino, or N-(C₁₋₃-alkyl)-aryl-C₁₋₃-alkyl-sulphonylamino group,
- e. a 2-oxo-imidazolidin-1-yl, 2,4-dioxo-imidazolidin-1-yl or 2,5-dioxo-imidazolidin-1-yl group wherein the nitrogen atom in the 3 position may in each case be substituted by a methyl or ethyl group,
- f. a cyano, carboxy, C₁₋₄-alkyloxy-carbonyl, aminocarbonyl, C₁₋₃-alkyl-aminocarbonyl, di-(C₁₋₃-alkyl)-aminocarbonyl, pyrrolidin-1-yl-carbonyl, piperidin-1-yl-carbonyl, morpholin-4-yl-carbonyl, piperazin-1-yl-carbonyl or 4-(C₁₋₃-alkyl)-piperazin-1-yl-carbonyl group,
- g. a C₁₋₃-alkyl-carbonyl or an arylcarbonyl group,
- h. a carboxy-C₁₋₃-alkyl, C₁₋₃-alkyloxy-carbonyl-C₁₋₃-alkyl, cyano-C₁₋₃-

- alkyl, aminocarbonyl-C₁₋₃-alkyl, C₁₋₃-alkyl-aminocarbonyl-C₁₋₃-alkyl, di-(C₁₋₃-alkyl)-aminocarbonyl-C₁₋₃-alkyl, pyrrolidin-1-yl-carbonyl-C₁₋₃-alkyl, piperidin-1-yl-carbonyl-C₁₋₃-alkyl, morpholin-4-yl-carbonyl-C₁₋₃-alkyl, piperazin-1-yl-carbonyl-C₁₋₃-alkyl or 4-(C₁₋₃-alkyl)-piperazin-1-yl-carbonyl-C₁₋₃-alkyl group,
- i. a carboxy-C₁₋₃-alkyloxy, C₁₋₃-alkyloxy-carbonyl-C₁₋₃-alkyloxy, cyano-C₁₋₃-alkyloxy, aminocarbonyl-C₁₋₃-alkyloxy, C₁₋₃-alkyl-aminocarbonyl-C₁₋₃-alkyloxy, di-(C₁₋₃-alkyl)-aminocarbonyl-C₁₋₃-alkyloxy, pyrrolidin-1-yl-carbonyl-C₁₋₃-alkyl-oxy, piperidin-1-yl-carbonyl-C₁₋₃-alkyloxy, morpholin-4-yl-carbonyl-C₁₋₃-alkyl-oxy, piperazin-1-yl-carbonyl-C₁₋₃-alkyloxy or 4-(C₁₋₃-alkyl)-piperazin-1-yl-carbonyl-C₁₋₃-alkyloxy group,
- j. a hydroxy-C₁₋₃-alkyl, C₁₋₃-alkyloxy-C₁₋₃-alkyl, amino-C₁₋₃-alkyl, C₁₋₃-alkylamino-C₁₋₃-alkyl, di-(C₁₋₃-alkyl)-amino-C₁₋₃-alkyl, pyrrolidin-1-yl-C₁₋₃-alkyl, piperidin-1-yl-C₁₋₃-alkyl, morpholin-4-yl-C₁₋₃-alkyl, piperazin-1-yl-C₁₋₃-alkyl, 4-(C₁₋₃-alkyl)-piperazin-1-yl-C₁₋₃-alkyl group,
- k. a hydroxy-C₁₋₃-alkyloxy, C₁₋₃-alkyloxy-C₁₋₃-alkyloxy, C₁₋₃-alkylsulphonyl-C₁₋₃-alkyloxy, C₁₋₃-alkylsulphinyl-C₁₋₃-alkyloxy, C₁₋₃-alkylsulphonyl-C₁₋₃-alkyloxy, amino-C₁₋₃-alkyloxy, C₁₋₃-alkylamino-C₁₋₃-alkyloxy, di-(C₁₋₃-alkyl)-amino-C₁₋₃-alkyloxy, pyrrolidin-1-yl-C₁₋₃-alkyloxy, piperidin-1-yl-C₁₋₃-alkyloxy, morpholin-4-yl-C₁₋₃-alkyloxy, piperazin-1-yl-C₁₋₃-alkyloxy, 4-(C₁₋₃-alkyl)-piperazin-1-yl-C₁₋₃-alkyloxy group,
- l. a mercapto, C₁₋₃-alkylsulphonyl, C₁₋₃-alkylsulphinyl, arylsulphonyl,

- C₁₋₃-alkylsulphonyl, arylsulphonyl, C₁₋₃-alkylsulphonyloxy, arylsulphonyloxy, trifluoromethylsulphanyl, trifluoromethylsulphinyl or trifluoromethylsulphonyl group,
- m. a sulpho, aminosulphonyl, C₁₋₃-alkyl-aminosulphonyl, di-(C₁₋₃-alkyl)-aminosulphonyl, pyrrolidin-1-yl-sulphonyl, piperidin-1-yl-sulphonyl, morpholin-4-yl-sulphonyl, piperazin-1-yl-sulphonyl or 4-(C₁₋₃-alkyl)-piperazin-1-yl-sulphonyl group,
- n. a methyl or methoxy group substituted by 1 to 3 fluorine atoms,
- o. an ethyl or ethoxy group substituted by 1 to 5 fluorine atoms,
- p. a C₂₋₄-alkenyl or C₂₋₄-alkynyl group,
- q. a C₃₋₄-alkenyloxy or C₃₋₄-alkynyloxy group,
- r. a C₃₋₆-cycloalkyl or C₃₋₆-cycloalkyloxy group,
- s. a C₃₋₆-cycloalkyl-C₁₋₃-alkyl or C₃₋₆-cycloalkyl-C₁₋₃-alkyloxy group or
- t. an aryl, aryloxy, aryl-C₁₋₃-alkyl or aryl-C₁₋₃-alkyloxy group,
- ii. R¹¹ and R¹², which may be identical or different, in each case denote a fluorine, chlorine, bromine or iodine atom, a C₁₋₃-alkyl, trifluoromethyl, hydroxy or C₁₋₃-alkyloxy group or a cyano group, or
- iii. R¹¹ together with R¹², if they are bound to adjacent carbon atoms, also denote a methylenedioxy, difluoromethylenedioxy, straight-chain C₃₋₅-alkylene or –CH=CH-CH=CH- group, while the –CH=CH-CH=CH- group may be substituted by a fluorine, chlorine or bromine atom, by a methyl, trifluoromethyl, cyano, aminocarbonyl, aminosulphonyl,

methylsulphonyl, methylsulphonylamino, methoxy, difluoromethoxy or trifluoromethoxy group, and

- iv. R^{13} and R^{14} , which may be identical or different, in each case represent a fluorine, chlorine or bromine atom, a trifluoromethyl, C_{1-3} -alkyl or C_{1-3} -alkyloxy group,
- (b) a phenyl group which may be substituted by the groups R^{10} to R^{14} , where R^{10} to R^{14} are as hereinbefore defined in this claim,
- (c) a phenyl- C_{2-3} -alkenyl group wherein the phenyl moiety may be substituted by the groups R^{10} to R^{14} , where R^{10} to R^{14} are as hereinbefore defined in this claim, and the alkenyl group may be substituted by one to four fluorine atoms or methyl groups, while the substituents may be identical or different,
- (d) a phenyl- C_{2-3} -alkynyl group wherein the phenyl moiety may be substituted by the groups R^{10} to R^{14} , where R^{10} to R^{14} are as hereinbefore defined in this claim,
- (e) a heteroaryl- C_{1-6} -alkyl group, while the C_{1-6} -alkyl group may be substituted by one to twelve fluorine atoms,
- (f) a heteroaryl group,

(g) a heteroaryl-C₂₋₃-alkenyl group, while the alkenyl group may be substituted by one to four fluorine atoms or methyl groups, while the substituents may be identical or different, or

(h) a heteroaryl-C₂₋₃-alkynyl group and

(II) B denotes

(a) an E-G group, wherein E is linked to the group A and

1. E denotes

- a. an oxygen or sulphur atom,
- b. an -NR_a- group wherein R_a denotes a hydrogen atom, a C₁₋₆-alkyl, C₃₋₆-alkenyl, C₃₋₆-alkynyl, C₃₋₇-cycloalkyl, phenyl, phenylmethyl, heteroaryl, heteroarylmethyl, amino, C₁₋₆-alkylamino, di-(C₁₋₆-alkyl)amino, hydroxy, C₁₋₆-alkyloxy group, while the above-mentioned phenyl rings may each be substituted by the groups R¹⁰ to R¹¹, while R¹⁰ to R¹¹ are as hereinbefore defined in this claim,
- c. an -NR_a-NR_a- group wherein R_a is as hereinbefore defined in this claim and the two groups R_a may be identical or different,
- d. an -NH-NH- group wherein the two hydrogen atoms are replaced by a straight-chain C₃₋₅-alkylene bridge,
- e. an -O-NR_a- group wherein R_a is as hereinbefore defined in this claim and the oxygen atom is linked to the group A and the nitrogen atom is linked to the group G,

- f. a $-O-CR_bR_c-$ group wherein the oxygen atom is linked to the group A and the carbon atom is linked to the group G and wherein R_b and R_c , which may be identical or different, denote a hydrogen or fluorine atom, a C_{1-6} -alkyl, C_{3-7} -cycloalkyl, phenyl, phenylmethyl, while the phenyl rings may each be substituted by the groups R^{10} to R^{14} , while R^{10} to R^{14} are as hereinbefore defined in this claim, or a heteroaryl or heteroaryl-methyl group or R_b and R_c together denote a straight-chain C_{2-6} -alkylene group,
- g. a $-S-CR_bR_c-$ group wherein the sulphur atom is linked to the group A and the carbon atom is linked to the group G and R_b and R_c , which may be identical or different, are as hereinbefore defined in this claim,
- h. a $-SO-CR_bR_c-$ group wherein the sulphur atom is linked to the group A and the carbon atom is linked to the group G and R_b and R_c , which may be identical or different, are as hereinbefore defined in this claim,
- i. a $-SO_2-CR_bR_c-$ group wherein the sulphur atom is linked to the group A and the carbon atom is linked to the group G and R_b and R_c , which may be identical or different, are as hereinbefore defined in this claim,
- j. or a $-NR_a-CR_bR_c-$ group wherein the nitrogen atom is linked to the group A and the carbon atom is linked to the group G and R_a , R_b and R_c , which may be identical or different, are as hereinbefore defined in this claim, and

2. G denotes

- a. a carbonyl or thiocarbonyl group,
- b. a methylene group substituted by an imino group wherein the nitrogen atom may be substituted by a C₁₋₆-alkyl, C₃₋₆-alkenyl, C₃₋₆-alkynyl, C₃₋₇-cycloalkyl, phenyl, phenylmethyl, heteroaryl, heteroarylmethyl, amino, C₁₋₆-alkylamino, di-(C₁₋₆-alkyl)amino, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, C₁₋₆-alkyl-carbonylamino, phenylcarbonylamino, C₁₋₆-alkyloxy-carbonylamino, C₁₋₆-alkylsulphonylamino, phenylsulphonylamino, hydroxyl, C₁₋₆-alkyloxy, cyano or nitro group, while the above-mentioned phenyl groups may be substituted by the groups R¹⁰ to R¹⁴, where R¹⁰ to R¹⁴ are as hereinbefore defined in this claim,
- c. a 1,1-ethenylene group wherein the carbon atom in the exo position may be substituted by one or two chlorine or fluorine atoms or one or two C₁₋₆-alkyl, C₁₋₆-perfluoroalkyl, C₃₋₆-alkenyl, C₃₋₆-alkynyl, C₃₋₇-cycloalkyl, phenyl, phenylmethyl, heteroaryl, heteroarylmethyl, C₁₋₆-alkyl-carbonyl, C₃₋₇-cycloalkyl-carbonyl, phenylcarbonyl, heteroarylcarbonyl, carboxy, C₁₋₆-alkyloxy-carbonyl, aminocarbonyl, C₁₋₆-alkylaminocarbonyl, di-(C₁₋₆-alkyl)aminocarbonyl, pyrrolidin-1-ylcarbonyl, piperidin-1-ylcarbonyl, morpholin-4-ylcarbonyl, phenylaminocarbonyl, heteroarylaminocarbonyl, C₁₋₆-

alkylsulphinyl, C₃₋₇-cycloalkylsulphinyl, phenylsulphinyl, heteroarylsulphinyl, C₁₋₆-alkylsulphonyl, C₃₋₇-cycloalkylsulphonyl, phenylsulphonyl, heteroarylsulphonyl, cyano or nitro groups, while the substituents may be identical or different and the above-mentioned phenyl groups may be substituted by the groups R¹⁰ to R¹⁴, while R¹⁰ to R¹⁴ are as hereinbefore defined in this claim,

d. or represent a sulphinyl or sulphonyl group,

(III) or A together with B denotes a 1,2,3,4-tetrahydroquinolinyldicarbonyl, 1,2,3,4-tetrahydroisoquinolinyldicarbonyl, 2,3-dihydroindolinyldicarbonyl or 2,3-dihydroisindolinyldicarbonyl group wherein the benzo groups may in each case be substituted by the groups R¹⁰ to R¹³, while R¹⁰ to R¹³ are as hereinbefore defined in this claim and one or two carbon atoms of the benzo group may be replaced by nitrogen atoms and the alkylene moieties of the above-mentioned groups may in each case be substituted by one or two fluorine atoms, one or two methyl groups or an oxo group, while the substituents may be identical or different, and

(IV) D denotes

- (a) a C₁₋₆-alkylene group which may be substituted by one to twelve fluorine atoms,
- (b) a C₂₋₃-alkenylene group which may be substituted by one to four fluorine atoms or methyl groups,
- (c) or a propynylene group,

R² denotes

- (I) a hydrogen atom,
- (II) a C₁₋₆-alkyl group,
- (III) a C₂₋₄-alkenyl group,
- (IV) a C₃₋₄-alkynyl group,
- (V) a C₃₋₆-cycloalkyl group,
- (VI) a C₃₋₆-cycloalkyl-C₁₋₃-alkyl group,
- (VII) a tetrahydrofuran-3-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl,
tetrahydrofuran-ylmethyl or tetrahydropyran-ylmethyl group,
- (VIII) an aryl group,
- (IX) an aryl-C₁₋₄-alkyl group,
- (X) an aryl-C₂₋₃-alkenyl group,
- (XI) an arylcarbonyl-C₁₋₂-alkyl group,

- (XII) a heteroaryl-C₁₋₃-alkyl group,
- (XIII) a furanilylcarbonylmethyl, thienylcarbonylmethyl, thiazolylcarbonylmethyl or pyridylcarbonylmethyl group,
- (XIV) a C₁₋₄-alkyl-carbonyl-C₁₋₂-alkyl group,
- (XVI) a C₃₋₆-cycloalkyl-carbonyl-C₁₋₂-alkyl group,
- (XVII) an aryl-G-C₁₋₃-alkyl group, while G denotes an oxygen or sulphur atom, an imino, C₁₋₃-alkylimino, sulphinyl or sulphonyl group,
- (XVIII) a C₁₋₄-alkyl group substituted by a group R_d, wherein R_d denotes a cyano, carboxy, C₁₋₃-alkyloxy-carbonyl, aminocarbonyl, C₁₋₃-alkylamino-carbonyl, di-(C₁₋₃-alkyl)-amino-carbonyl, pyrrolidin-1-ylcarbonyl, piperidin-1-ylcarbonyl, morpholin-4-ylcarbonyl, piperazin-1-ylcarbonyl, 4-methylpiperazin-1-ylcarbonyl or 4-ethylpiperazin-1-ylcarbonyl group, or
- (XIX) a C₂₋₄-alkyl group substituted by a group R_e, where R_e denotes a hydroxy, C₁₋₃-alkyloxy, amino, C₁₋₃-alkylamino, di-(C₁₋₃-alkyl)-amino, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl, piperazin-1-yl, 4-methyl-piperazin-1-yl or 4-ethyl-piperazin-1-yl group and is isolated from the cyclic nitrogen atom in the 3 position of the xanthine structure by at least two carbon atoms,

R³ denotes

- (I) a C₃₋₈-alkyl group,
- (II) a C₁₋₃-alkyl group substituted by a group R_f, where R_f denotes a C₃₋₇-cyclo-alkyl group optionally substituted by one or two C₁₋₃-alkyl groups or a C₅₋₇-cycloalkenyl group optionally substituted by one or two C₁₋₃-alkyl groups,
- (III) a C₃₋₈-alkenyl group,
- (IV) a C₃₋₆-alkenyl group substituted by a fluorine, chlorine or bromine atom or a trifluoromethyl group,
- (VI) a C₃₋₈-alkynyl group,
- (VII) an aryl group or
- (VIII) an aryl-C₂₋₄-alkenyl group,

and

R¹ denotes

- (I) an azetidin-1-yl or pyrrolidin-1-yl group which is substituted in the 3 position by an amino, C₁₋₃-alkylamino or a di-(C₁₋₃-alkyl)amino group and may additionally be substituted by one or two C₁₋₃-alkyl groups,

- (II) a piperidin-1-yl or hexahydroazepin-1-yl group which is substituted in the 3 position or in the 4 position by an amino, C_{1,3}-alkylamino or di-(C_{1,3}-alkyl)amino group and may additionally be substituted by one or two C_{1,3}-alkyl groups,
- (III) a 3-amino-piperidin-1-yl group wherein the piperidin-1-yl-moiety is additionally substituted by an aminocarbonyl, C_{1,2}-alkyl-aminocarbonyl, di-(C_{1,2}-alkyl)aminocarbonyl, pyrrolidin-1-yl-carbonyl, (2-cyano-pyrrolidin-1-yl)carbonyl, thiazolidin-3-yl-carbonyl, (4-cyano-thiazolidin-3-yl)carbonyl, piperidin-1-ylcarbonyl or morpholin-4-ylcarbonyl group,
- (IV) a 3-amino-piperidin-1-yl group wherein the piperidin-1-yl-moiety in the 4 position or in the 5 position is additionally substituted by a hydroxy or methoxy group,
- (V) a 3-amino-piperidin-1-yl group wherein the methylene group in the 2 position or in the 6 position is replaced by a carbonyl group,
- (VI) a piperidin-1-yl or hexahydroazepin-1-yl group substituted in the 3 position by an amino, C_{1,3}-alkylamino or di-(C_{1,3}-alkyl)-amino group, wherein in each case two hydrogen atoms on the carbon skeleton of the piperidin-1-yl or hexahydroazepin-1-yl- group are replaced by a straight-chain alkylene bridge, this bridge containing 2 to 5 carbon atoms if the two hydrogen atoms are located on the same carbon atom, or 1 to 4 carbon atoms if the hydrogen atoms are located on adjacent carbon atoms, or 1 to 4 carbon atoms if the

hydrogen atoms are located on carbon atoms separated by one atom, or 1 to 3 carbon atoms if the two hydrogen atoms are located on carbon atoms separated by two atoms,

(VII) an azetidin-1-yl, pyrrolidin-1-yl, piperidin-1-yl or hexahydroazepin-1-yl group which is substituted by an amino- $C_{1,3}$ -alkyl, $C_{1,3}$ -alkylamino- $C_{1,3}$ -alkyl or a di-($C_{1,3}$ -alkyl)amino- $C_{1,3}$ -alkyl group,

(VIII) a piperazin-1-yl or [1,4]diazepan-1-yl group optionally substituted on the carbon skeleton by one or two $C_{1,3}$ -alkyl groups, while R^4 cannot represent a piperazin-1-yl or [1,4]diazepan-1-yl group optionally substituted on the carbon skeleton by one or two $C_{1,3}$ -alkyl groups in those compounds wherein

- (a) the group E denotes an oxygen atom and the group G denotes a carbonyl group,
- (b) the group E denotes an oxygen atom and the group G denotes a sulphonyl group,
- (c) the group E denotes an $-NR_a-$ group and the group G denotes a carbonyl group wherein R_a is as hereinbefore defined in this claim,
- (d) the group E denotes an $-NR_a-$ group wherein R_a is as hereinbefore defined in this claim, and
- (e) the group G denotes a sulphonyl group or the group A denotes a phenyl or heteroaryl group optionally substituted by one of the above-mentioned groups and the group E denotes an oxygen atom and the group G denotes an ethenylene group,

- (IX) a 3-imino-piperazin-1-yl, 3-imino-[1,4]diazepan-1-yl or 5-imino-[1,4]diazepan-1-yl group optionally substituted on the carbon skeleton by one or two C₁₋₃-alkyl groups,
- (X) a [1,4]diazepan-1-yl group optionally substituted by one or two C₁₋₃-alkyl groups which is substituted in the 6 position by an amino group,
- (XI) a C₃₋₇-cycloalkyl group which is substituted by an amino, C₁₋₃-alkylamino or di-(C₁₋₃-alkyl)-amino group,
- (XII) a C₃₋₇-cycloalkyl group which is substituted by an amino-C₁₋₃-alkyl, C₁₋₃-alkylamino-C₁₋₃-alkyl or a di-(C₁₋₃-alkyl)amino-C₁₋₃-alkyl group,
- (XIII) a C₃₋₇-cycloalkyl-C₁₋₂-alkyl group wherein the cycloalkyl moiety is substituted by an amino, C₁₋₃-alkylamino or di-(C₁₋₃-alkyl)-amino group,
- (XIV) a C₃₋₇-cycloalkyl-C₁₋₂-alkyl group wherein the cycloalkyl moiety is substituted by an amino-C₁₋₃-alkyl, C₁₋₃-alkylamino-C₁₋₃-alkyl or a di-(C₁₋₃-alkyl)amino-C₁₋₃-alkyl group,
- (XV) a C₃₋₇-cycloalkylamino group wherein the cycloalkyl moiety is substituted by an amino, C₁₋₃-alkylamino or di-(C₁₋₃-alkyl)-amino group, while the two nitrogen atoms on the cycloalkyl moiety are separated from one another by at least two carbon atoms,

- (XVI) an N-(C₃₋₇-cycloalkyl)-N-(C₁₋₃-alkyl)-amino group wherein the cycloalkyl moiety is substituted by an amino, C₁₋₃-alkylamino or di-(C₁₋₃-alkyl)-amino group, while the two nitrogen atoms on the cycloalkyl moiety are separated from one another by at least two carbon atoms,
- (XVII) a C₃₋₇-cycloalkylamino group wherein the cycloalkyl moiety is substituted by an amino-C₁₋₃-alkyl, C₁₋₃-alkylamino-C₁₋₃-alkyl or a di-(C₁₋₃-alkyl)amino-C₁₋₃-alkyl group,
- (XVIII) an N-(C₃₋₇-cycloalkyl)-N-(C₁₋₃-alkyl)-amino group wherein the cycloalkyl moiety is substituted by an amino-C₁₋₃-alkyl, C₁₋₃-alkylamino-C₁₋₃-alkyl or a di-(C₁₋₃-alkyl)amino-C₁₋₃-alkyl group,
- (XIX) a C₃₋₇-cycloalkyl-C₁₋₂-alkyl-amino group wherein the cycloalkyl moiety is substituted by an amino, C₁₋₃-alkylamino or di-(C₁₋₃-alkyl)-amino group,
- (XX) an N-(C₃₋₇-cycloalkyl-C₁₋₂-alkyl)-N-(C₁₋₂-alkyl)-amino group wherein the cycloalkyl moiety is substituted by an amino, C₁₋₃-alkylamino or di-(C₁₋₃-alkyl)-amino group,
- (XXI) a C₃₋₇-cycloalkyl-C₁₋₂-alkyl-amino group wherein the cycloalkyl moiety is substituted by an amino-C₁₋₃-alkyl, C₁₋₃-alkylamino-C₁₋₃-alkyl or a di-(C₁₋₃-alkyl)amino-C₁₋₃-alkyl group,

(XXII) an N-(C₃₋₇-cycloalkyl-C₁₋₂-alkyl)-N-(C₁₋₂-alkyl)-amino group wherein the cycloalkyl moiety is substituted by an amino-C₁₋₃-alkyl, C₁₋₃-alkylamino-C₁₋₃-alkyl or a di-(C₁₋₃-alkyl)amino-C₁₋₃-alkyl group,

(XXIII) a R¹⁹-C₂₋₄-alkylamino group wherein R¹⁹ is separated from the nitrogen atom of the C₂₋₄-alkylamino moiety by at least two carbon atoms and R¹⁹ denotes an amino, C₁₋₃-alkylamino or di-(C₁₋₃-alkyl)-amino group,

(XXIV) an R¹⁹-C₂₋₄-alkylamino group wherein the nitrogen atom of the C₂₋₄-alkylamino moiety is substituted by a C₁₋₃-alkyl group and R¹⁹ is separated from the nitrogen atom of the C₂₋₄-alkylamino moiety by at least two carbon atoms, while R¹⁹ is as hereinbefore defined in this claim,

(XXV) an amino group substituted by the group R²⁰ wherein R²⁰ denotes an azetidin-3-yl, azetidin-2-ylmethyl, azetidin-3-ylmethyl, pyrrolidin-3-yl, pyrrolidin-2-ylmethyl, pyrrolidin-3-ylmethyl, piperidin-3-yl, piperidin-4-yl, piperidin-2-ylmethyl, piperidin-3-ylmethyl or piperidin-4-ylmethyl group, while the groups mentioned for R²⁰ may in each case be substituted by one or two C₁₋₃-alkyl groups,

(XXVI) an amino group substituted by the group R²⁰ and a C₁₋₃-alkyl group wherein R²⁰ is as hereinbefore defined in this claim, while the groups mentioned for R²⁰ may in each case be substituted by one or two C₁₋₃-alkyl groups,

- (XXVII) an R¹⁹-C3-4-alkyl group wherein the C3-4-alkyl moiety is straight-chain and may additionally be substituted by one or two C₁₋₃-alkyl groups, while R¹⁹ is as hereinbefore defined in this claim,
- (XXVIII) a 3-amino-2-oxo-piperidin-5-yl or 3-amino-2-oxo-1-methyl-piperidin-5-yl group,
- (XXIX) a pyrrolidin-3-yl, piperidin-3-yl, piperidin-4-yl, hexahydroazepin-3-yl or hexahydroazepin-4-yl group which is substituted in the 1 position by an amino, C₁₋₃-alkylamino or di-(C₁₋₃-alkyl)amino group, or
- (XXX) an azetidin-2-yl-C₁₋₂-alkyl, azetidin-3-yl-C₁₋₂-alkyl, pyrrolidin-2-yl-C₁₋₂-alkyl, pyrrolidin-3-yl, pyrrolidin-3-yl-C₁₋₂-alkyl, piperidin-2-yl-C₁₋₂-alkyl, piperidin-3-yl, piperidin-3-yl-C₁₋₂-alkyl, piperidin-4-yl or piperidin-4-yl-C₁₋₂-alkyl group, while the above-mentioned groups may in each case be substituted by one or two C₁₋₃-alkyl groups,

while by the aryl groups mentioned in the definition of the above groups are meant phenyl or naphthyl groups, which may be mono- or disubstituted by R_b independently of one another, where the substituents are identical or different and R_b denotes a fluorine, chlorine, bromine or iodine atom, a trifluoromethyl, cyano, nitro, amino, aminocarbonyl, aminosulphonyl, methylsulphonyl, acetylamino, methylsulphonylamino, C₁₋₄-alkyl, C₁₋₃-alkyl-carbonyl, cyclopropyl, ethenyl, ethynyl, hydroxy, C₁₋₄-alkyloxy, C₁₋₄-alkoxy-carbonyl, methylsulphinyl, phenylsulphinyl, methylsulphonyl, phenylsulphonyl, difluoromethoxy or trifluoromethoxy group,

by the heteroaryl groups mentioned in the definitions of the above-mentioned groups are meant a pyrrolyl, furanyl, thienyl, pyridyl, indolyl, benzofuranyl, benzothiophenyl, quinoliny or isoquinoliny group,

or a pyrrolyl, furanyl, thienyl or pyridyl group wherein one or two methyne groups are replaced by nitrogen atoms,

or an indolyl, benzofuranyl, benzothiophenyl, quinoliny or isoquinoliny group wherein one to three methyne groups are replaced by nitrogen atoms,

or a 1,2-dihydro-2-oxo-pyridinyl, 1,4-dihydro-4-oxo-pyridinyl, 2,3-dihydro-3-oxo-pyridazinyl, 1,2,3,6-tetrahydro-3,6-dioxo-pyridazinyl, 1,2-dihydro-2-oxo-pyrimidinyl, 3,4-dihydro-4-oxo-pyrimidinyl, 1,2,3,4-tetrahydro-2,4-dioxo-pyrimidinyl, 1,2-dihydro-2-oxo-pyrazinyl, 1,2,3,4-tetrahydro-2,3-dioxo-pyrazinyl, 2,3-dihydro-2-oxo-indolyl, 2,3-dihydrobenzofuranyl, 2,3-dihydro-2-oxo-1*H*-benzimidazolyl, 2,3-dihydro-2-oxo-benzoxazolyl, 1,2-dihydro-2-oxo-quinoliny, 1,4-dihydro-4-oxo-quinoliny, 1,2-dihydro-1-oxo-isoquinoliny, 1,4-dihydro-4-oxo-cinnoliny, 1,2-dihydro-2-oxo-quinazoliny, 3,4-dihydro-4-oxo-quinazoliny, 1,2,3,4-tetrahydro-2,4-dioxo-quinazoliny, 1,2-dihydro-2-oxoquinoxaliny, 1,2,3,4-tetrahydro-2,3-dioxo-quinoxaliny, 1,2-dihydro-1-oxo-phthalazinyl, 1,2,3,4-tetrahydro-1,4-dioxo-phthalazinyl, chromanyl, cumariny, 2,3-dihydrobenzo[1,4]dioxiny or 3,4-dihydro-3-oxo-2*H*-benzo[1,4]oxazinyl group,

and the above-mentioned heteroaryl groups may be mono- or disubstituted by R_a, while the substituents may be identical or different and R_b is as hereinbefore defined in this claim,

and, unless otherwise stated, the above-mentioned alkyl, alkenyl and alkynyl groups may be straight-chain or branched,

the tautomers, the enantiomers, the diastereomers, the mixtures thereof, and the salts thereof.

2. (Previously presented) The compound of formula I according to claim 1, wherein

R^1 , R^2 and R^3 are defined as in claim 1 and

R^4 denotes

- (I) a pyrrolidin-1-yl group which is substituted in the 3 position by an amino group,
- (II) a piperidin-1-yl group which is substituted in the 3 position by an amino group,
- (III) a hexahydroazepin-1-yl- group which is substituted in the 3 position or in the 4 position by an amino group,
- (IV) a (2-aminocyclohexyl)amino group,
- (V) a cyclohexyl group which is substituted in the 3 position by an amino group,

or

- (VI) an *N*-(2-aminoethyl)-*N*-methylamino or an *N*-(2-aminoethyl)-*N*-ethylamino group,

while, unless otherwise mentioned, the above-mentioned alkyl, alkenyl and alkynyl groups may be straight-chain or branched,

the tautomers, the enantiomers, the diastereomers, the mixtures thereof and the salts thereof.

3. (Previously presented) The compound of formula I according to claim 2, wherein

R¹ denotes an A-B-D group wherein

A denotes a phenyl, phenylmethyl, 1-phenylethyl, pyridinyl, pyridinylmethyl, 1-pyridinylethyl, pyrimidinyl, pyrimidinylmethyl, pyrazinyl, pyrazinylmethyl, 1,3,5-triazinyl, 1,3,5-triazinylmethyl, 1,2,4-triazinyl, 1,2,4-triazinylmethyl, furanyl, thienyl, pyrrolyl, imidazolyl, 1,3-oxazolyl group, while the above-mentioned phenyl and heteroaryl groups may be substituted by a fluorine, chlorine or bromine atom or by a C₁₋₄-alkyl, C₁₋₄-alkoxy, trifluoromethyl, cyano, C₁₋₃-alkyl-carbonyl, C₁₋₄-alkoxy-carbonyl, methylsulphinyl, phenylsulphinyl, methylsulphonyl, phenylsulphonyl, amino or nitro group and may optionally additionally be substituted by a fluorine, chlorine or bromine atom or by a C₁₋₄-alkyl, C₁₋₄-alkoxy, trifluoromethyl or cyano group, while the substituents may be identical or different, and

B denotes an E-G group wherein E is linked to the group A and

E denotes an oxygen atom, an -NH-, -N(CH₃)- or -NH-NH- group or a -OCH₂- group wherein the oxygen atom is linked to the group A and the carbon atom is linked to the group G, and

G denotes a carbonyl group, a cyanoiminomethylene or nitroiminomethylene group, or a 1,1-ethenylene group wherein the carbon atom in the exo position may

be substituted by one or two trifluoromethyl, cyano, nitro, C₁₋₃-alkyloxy-carbonyl, C₁₋₄-alkyl-carbonyl, phenylcarbonyl, C₁₋₃-alkylsulphinyl, phenylsulphinyl, C₁₋₃-alkylsulphonyl or phenylsulphonyl groups, while the substituents may be identical or different and the above-mentioned phenyl groups may be substituted by one or two fluorine, chlorine or bromine atoms or one or two C₁₋₃-alkyl, trifluoromethyl, C₁₋₃-alkoxy, cyano, C₁₋₃-alkyl-carbonyl, C₁₋₃-alkoxy-carbonyl, methylsulphinyl, phenylsulphinyl, methylsulphonyl, phenylsulphonyl or nitro groups, while these substituents may also be identical or different,

or A and B together denote a 1,2,3,4-tetrahydroquinolin-1-ylcarbonyl or 1,2,3,4-tetrahydroisoquinolin-2-ylcarbonyl group and

D denotes a methylene group,

R² denotes a hydrogen atom or a C₁₋₃-alkyl group,

R³ denotes a C₄₋₆-alkenyl group, a 2-buten-1-yl group, or a 1-cyclopenten-1-yl-methyl group, and

R⁴ denotes a piperidin-1-yl group which is substituted in the 3 position by an amino group, a hexahydroazepin-1-yl- group which is substituted in the 3 position or in the 4 position by an amino group, a (2-aminocyclohexyl)amino group, a cyclohexyl group which is substituted in the 3 position by an amino group, or an *N*-(2-aminoethyl)-*N*-methylamino or an *N*-(2-aminoethyl)-*N*-ethylamino group,

while, unless otherwise mentioned, the above-mentioned alkyl, alkenyl and alkynyl groups may be straight-chain or branched,

the tautomers, the enantiomers, the diastereomers, the mixtures thereof and the salts thereof.

4. (Previously presented) The compound of formula I according to claim 3, wherein

R¹ denotes an A-B-D group wherein

A denotes a phenyl, phenylmethyl, 1-phenylethyl, pyridinyl, pyridinylmethyl, 1-pyridinylethyl, pyrimidinyl or pyrimidinylmethyl group, where the phenyl moiety may be substituted by a fluorine, chlorine or bromine atom or by a C₁₋₄-alkyl, trifluoromethyl, C₁₋₄-alkoxy, cyano, C₁₋₃-alkyl-carbonyl, C₁₋₄-alkoxy-carbonyl, methylsulphinyl, phenylsulphinyl, methylsulphonyl, phenylsulphonyl, amino or nitro group and may optionally additionally be substituted by a fluorine, chlorine or bromine atom or by a C₁₋₄-alkyl, trifluoromethyl, C₁₋₄-alkoxy or cyano group, while the substituents may be identical or different, and

B denotes a E-G group wherein E is linked to the group A and

E denotes an oxygen atom, an -NH- group, -N(CH₃)- group or -OCH₂- group wherein the oxygen atom is linked to the group A and the carbon atom is linked to the group G, and

G denotes a carbonyl group,

or A and B together denote a 1,2,3,4-tetrahydroquinolin-1-ylcarbonyl or 1,2,3,4-tetrahydroisoquinolin-2-ylcarbonyl group and

D denotes a methylene group,

R² denotes a methyl group,

R³ denotes a 2-buten-1-yl, 3-methyl-2-buten-1-yl, or a 2-butyne-1-yl group

and

R⁴ denotes a (3-amino-piperidin-1-yl) group,

the tautomers, the enantiomers, the diastereomers, the mixtures thereof and the salts thereof.

5. **(Previously presented)** The compound of formula I according to claim 4, wherein

R¹ denotes an A-B-D group wherein

A denotes a phenyl, phenylmethyl, pyridinyl or pyridinylmethyl group wherein the phenyl rings may be substituted by an amino, methoxy, methyl, cyano or nitro group, and

B denotes an E-G group wherein E is linked to the group A and

E denotes an oxygen atom, an -NH- group or -OCH₂- group wherein the oxygen atom is linked to the group A and the carbon atom is linked to the group G, and

G denotes a carbonyl group,

or A and B together denote a 1,2,3,4-tetrahydroquinolin-1-ylcarbonyl or 1,2,3,4-tetrahydroisoquinolin-2-ylcarbonyl group and

D denotes a methylene group,

R² denotes a methyl group,

R³ denotes a 2-buten-1-yl, 3-methyl-2-buten-1-yl or a 2-butyne-1-yl group

and

R⁴ denotes a (3-amino-piperidin-1-yl) group,

the tautomers, the enantiomers, the diastereomers, the mixtures thereof and the salts thereof.

6. (Previously presented) The following compounds of formula I according to claim 1:

- (a) 1-[(benzyloxycarbonyl)methyl]-3-methyl-7-(2-buty-1-yl)-8-[(*R*)-3-amino-piperidin-1-yl]-xanthine,
- (b) 1-[(benzylaminocarbonyl)methyl]-3-methyl-7-(2-buty-1-yl)-8-[(*R*)-3-amino-piperidin-1-yl]-xanthine,
- (c) 1-[(phenylaminocarbonyl)methyl]-3-methyl-7-(2-buty-1-yl)-8-[(*R*)-3-amino-piperidin-1-yl]-xanthine,
- (d) 1-[[pyridin-2-yl]aminocarbonyl]methyl-3-methyl-7-(2-buty-1-yl)-8-[(*R*)-3-amino-piperidin-1-yl]-xanthine,
- (e) 1-[[pyridin-3-yl]methoxycarbonyl]methyl-3-methyl-7-(2-buty-1-yl)-8-[(*R*)-3-amino-piperidin-1-yl]-xanthine,
- (f) 1-[[pyridin-3-yl]aminocarbonyl]methyl-3-methyl-7-(2-buty-1-yl)-8-[(*R*)-3-amino-piperidin-1-yl]-xanthine,
- (g) 1-[[2-methyl-phenyl]aminocarbonyl]methyl-3-methyl-7-(2-buty-1-yl)-8-[(*R*)-3-amino-piperidin-1-yl]-xanthine,
- (h) 1-[[2-nitro-phenyl]aminocarbonyl]methyl-3-methyl-7-(2-buty-1-yl)-8-[(*R*)-3-amino-piperidin-1-yl]-xanthine,

- (i) 1-[[{(4-cyano-phenyl)aminocarbonyl]methyl}-3-methyl-7-(2-butyne-1-yl)-8-(3-amino-piperidin-1-yl)]-xanthine,
- (j) 1-[[{(2-methoxy-phenyl)aminocarbonyl]methyl}-3-methyl-7-(2-butyne-1-yl)-8-[(R)-3-amino-piperidin-1-yl]]-xanthine,
- (k) 1-(2-oxo-3-phenoxy-propyl)-3-methyl-7-(2-butyne-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine,
- (l) 1-[(2-amino-benzylaminocarbonyl)methyl]-3-methyl-7-(2-butyne-1-yl)-8-(3-amino-piperidin-1-yl)-xanthine,
- (m) 1-[2-(3,4-dihydro-1*H*-isoquinolin-2-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyne-1-yl)-8-[(R)-3-amino-piperidin-1-yl]-xanthine,
- (n) 1-[2-(3,4-dihydro-2*H*-quinolin-1-yl)-2-oxo-ethyl]-3-methyl-7-(2-butyne-1-yl)-8-[(R)-3-amino-piperidin-1-yl]-xanthine,
- (o) 1-[[{(3-cyano-phenyl)aminocarbonyl]methyl}-3-methyl-7-(2-butyne-1-yl)-8-(3-amino-piperidin-1-yl)]-xanthine,
- (p) 1-[(3-methoxy-benzoyloxycarbonyl)methyl]-3-methyl-7-(2-butyne-1-yl)-8-[(R)-3-amino-piperidin-1-yl]-xanthine and
- (q) 1-[(3-nitro-benzoyloxycarbonyl)methyl]-3-methyl-7-(2-butyne-1-yl)-8-[(R)-3-amino-

piperidin-1-yl]-xanthine

and the salts thereof.

7. (Canceled)

8. (Previously presented) A pharmaceutical composition containing the compound according to any one of claims 1 to 6 together with one or more inert carriers and/or diluents.

9. (Canceled)

10. (Currently amended) A method comprising administering to ~~the~~ a patient in need thereof a composition comprising the compound or physiologically acceptable salt thereof according to any one of claims 1 to 6 in an amount effective for the treatment of a disease or a condition selected from the group consisting of ~~type I and~~ type II diabetes mellitus, ~~arthritis~~, and obesity.


11. (Canceled)

12. (Previously presented) A process for preparing a pharmaceutical composition wherein the compound according to any one of claims 1 to 6 is incorporated in one or more inert carriers and/or diluents.

13. (Canceled)

14. (Previously presented) A process for preparing the compound of formula I according to claim 1 comprising the step of:

reacting a compound of formula II



wherein

R¹ to R³ are defined as in claim 1 and


Z¹ denotes a leaving group,

with an amine of formula R⁴-H, wherein R⁴ denotes one of the groups I to X or XV to XXVI of R⁴ in claim 1.

15. (Canceled)

16. (Currently amended) A method comprising administering to a patient in need thereof a compound according to one of claims 1 to 6 or a salt thereof in an amount effective for the treatment of a disease or a condition selected from the group consisting of type I and type II diabetes mellitus and obesity.

17. (Previously presented) A process for preparing the compound of formula I according to claim 1 comprising the step of deprotecting a compound of formula III



wherein R¹, R² and R³ are defined as in claim 1 and

R⁴ⁿ denotes one of the groups mentioned for R⁴ hereinbefore that contains an imino, amino, or alkylamino group, wherein the imino, amino or alkylamino group is substituted by a protective group.

18. (Previously presented) A method comprising administering to a patient in need thereof a compound according to one of claims 1 to 6 or a salt thereof in an amount effective for the prevention of a disease or a condition selected from the group consisting of type II diabetes mellitus and obesity.

19. (Currently Amended) A method of treating type I or type II diabetes mellitus, arthritis or obesity, comprising administering to a patient in need thereof a pharmaceutically effective amount of a compound according to one of claims 1 to 6 or a tautomer, enantiomer, diastereomer or mixture thereof, or a salt thereof, wherein the administering is of 1 to 100 mg of the compound by intravenous route, or of 1 to 1000 mg by oral route, in each case 1 to 4 times a day.

20. (Currently Amended) A method of treating ~~type I or~~ type II diabetes mellitus, arthritis or obesity, comprising administering to a patient in need thereof a pharmaceutically effective amount of a compound according to one of claims 1 to 6 or a tautomer, enantiomer, diastereomer or mixture thereof, or a salt thereof, wherein the administering is of 1 to 30 mg of the compound by intravenous route, or of 1 to 100 mg by oral route, in each case 1 to 4 times a day.